Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Teijin Pharma and Astellas Pharma have signed an agreement to distribute febuxostat (TMX-67) in India and Southeast Asia.
Subscribe to our email newsletter
Febuxostat is indicated as a treatment for gout and hyperuricemia.
The agreement allows Astellas Pharma to sell the product in India, Indonesia, Thailand, the Philippines, Malaysia, Vietnam and Singapore.
Astellas Pharma is responsible for seeking marketing approval in each of these countries, with the goal of beginning sales by 2015.